Additional file 2 of Whole genome sequencing of the pulmonary microbiome in interstitial lung disease subtypes by Kristel S. Knudsen (10535406)

“…Every red dot on the plot represents differentially abundant species with increased significance noted towards the top of the plot. Grey dot: not significant…”

Elevated serum sFlt-1 at 18–20 weeks in advanced maternal age: a key difference from younger pregnancies by Kazunari Nemoto (22495831)

“…In non-AMA pregnancies, serum sFlt-1 levels tended to be lower in PE cases compared to normotensive (NT) cases. Conversely, in AMA pregnancies, PE cases showed significantly higher serum sFlt-1 levels and sFlt-1/PlGF ratios than NT cases. …”

Table 1_Unpacking the cost implications of diagnosis-related groups reform for lumbar disc herniation patients in Chinese medicine: a closer look at evidence from China.xls by Meng-en Chen (22274533)

“…Objectives<p>Lumbar disc herniation (LDH) presents a significant economic burden globally, worsening in China due to an aging population. …”

Table 1_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.xlsx by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Image 2_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.jpeg by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Data Sheet 1_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.pdf by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Image 1_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.jpeg by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Image 3_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.jpeg by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Image 5_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.jpeg by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Image 4_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.jpeg by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Table 2_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.xlsx by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Table 1_Efficacy and safety of sofosbuvir plus daclatasvir in hemodialysis patients with genotype 1b or 2a hepatitis C virus infection: a single-arm, prospective real-world study.x... by Kaili Wang (2246485)

“…One participant was lost to follow-up. APRI scores significantly decreased from baseline (0.56) to week 24 (0.20, p < 0.001). …”

Data Sheet 2_Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus.docx by Haoyi Yang (8215116)

“…In particular, the increase in bile acid-related metabolites in the 2 mg BID group was significantly greater than that in the placebo group, and unsaturated fatty acid-related metabolites decreased in both the 2 mg BID group and the placebo group, but there was no significant difference between the two groups. …”

Table 1_Disorders of acid-base balance promote rumen lipopolysaccharide biosynthesis in dairy cows by modulating the microbiome.xls by Guobin Hou (20207727)

“…Introduction<p>Disorders of acid-base balance in the rumen of dairy cows have a significant impact on their health and performance. …”

Data Sheet 3_Association between sarcopenia and outcomes of surgically treated oral squamous cell carcinoma: a systematic review and meta‐analysis.pdf by Kai Luo (769190)

“…The one-year OS (OR = 0.71, 95% CI = 0.67-0.75, P < 0.00001) and five-year OS (OR = 0.60, 95% CI = 0.45-0.79, P = 0.0003) decreased significantly. Patients with sarcopenia had significantly increased 30-day postoperative mortality and an also increased risk of pneumonia (OR = 1.36, 95% CI = 1.24-1.49, P < 0.00001) and surgical site infection (OR = 2.49, 95% CI = 1.06-5.84, P = 0.04).…”

Data Sheet 1_Immunogenic cell death-related biomarkers in heart failure probed by transcriptome and single-cell sequencing.zip by Haoyue Wang (13138179)

“…In addition, the expression levels of CD163 and VSIG4 increased in subpopulations of monocytes and macrophages, whereas FPR1 showed a decreasing trend. RT-qPCR results confirmed significant down-regulation of CD163, FPR1, and VSIG4 in patients with HF and animal models.…”

Data Sheet 1_Invasive treatment strategy for older patients with non-ST-elevation acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials.pdf by Vaibhav Vats (18702889)

“…Invasive management significantly decreased the risk of MI (RR 0.70, 95% CI: 0.55, 0.89) and revascularization (RR 0.29, 95% CI: 0.21, 0.40). …”

Data Sheet 2_Association between sarcopenia and outcomes of surgically treated oral squamous cell carcinoma: a systematic review and meta‐analysis.pdf by Kai Luo (769190)

“…The one-year OS (OR = 0.71, 95% CI = 0.67-0.75, P < 0.00001) and five-year OS (OR = 0.60, 95% CI = 0.45-0.79, P = 0.0003) decreased significantly. Patients with sarcopenia had significantly increased 30-day postoperative mortality and an also increased risk of pneumonia (OR = 1.36, 95% CI = 1.24-1.49, P < 0.00001) and surgical site infection (OR = 2.49, 95% CI = 1.06-5.84, P = 0.04).…”

Table 1_Association between sarcopenia and outcomes of surgically treated oral squamous cell carcinoma: a systematic review and meta‐analysis.docx by Kai Luo (769190)

“…The one-year OS (OR = 0.71, 95% CI = 0.67-0.75, P < 0.00001) and five-year OS (OR = 0.60, 95% CI = 0.45-0.79, P = 0.0003) decreased significantly. Patients with sarcopenia had significantly increased 30-day postoperative mortality and an also increased risk of pneumonia (OR = 1.36, 95% CI = 1.24-1.49, P < 0.00001) and surgical site infection (OR = 2.49, 95% CI = 1.06-5.84, P = 0.04).…”

Table 1_Denosumab in patients with osteogenesis imperfecta and a historical control study with alendronate.docx by Yazhao Mei (13041882)

“…Vertebral area loss decreased significantly with denosumab (-14.6%, P=0.029), unlike alendronate (-8.8%, P=0.296). …”